摘要
目的探讨早期应用辛伐他汀对急性冠状动脉综合征患者临床治疗效果的影响。方法将94例急性冠状动脉综合征患者,随机分为观察组和对照组。对照组患者加用谷维素片治疗,观察组患者入院后24h加用辛伐他汀治疗。比较分析两组患者治疗前后血脂和超敏C反应蛋白的变化情况、治疗后心血管事件的发生情况以及不良反应的发生情况。结果两组患者治疗后TC、TG、LDL-C以及hs-CRP明显降低,差异具有统计学意义(P<0.05)。与对照组患者相比,观察组患者TC、TG、LDL-C以及hs-CRP也明显降低,差异均具有统计学意义(P<0.05)。与此同时,与对照组患者相比,观察组患者急性心肌梗死再发、脑卒中再发以及再次住院等心血管事件的发生率均明显下降,ALT/AST增高、头晕以及胃肠道反应的发生率均明显下降,差异均具有统计学意义(P<0.05)。结论早期应用辛伐他汀药物能够明显改善急性冠状动脉综合征患者血脂和炎症相关因子,进而降低患者不良反应及心血管疾病事件的发生,促进患者的预后康复。
Objective To explore the effect of early application of simvastatin treatment for acute coronary syndrome. Methods 94 patients were divided into observation group and control group randomly. The patients in the control group were treated with oryzanol piece. The patients in the observation group were treated with simvastatin after 24 h in hospital. The changes of blood lipids, high sensitivity C-reactive protein, the occurrence of cardiovascular events after treatment and the adverse reactions before and after treatment of patients in the two groups were compared and analyzed. Results After treatment, the TC, TG, LDL-C and hs-CRP of the two groups were lower significantly, with statistically significant （P 〈0.05）. Compared with control group, TC, TG, LDL-C and hs-CRP of patients in the observation group were lower significantly, with statistically significant （P〈0.05）. At the same time, compared with control group, the acute recurrent myocardial infarction, stroke recurrence, and rehospitalization cardiovascular events of patients in the observation group decreased significantly, ALT/AST increased, incidence of dizziness and gastrointestinal reactions decreased significantly, with statistically significant （P 〈0.05）. Conclusions Early application of simvastatin can significantly improve hyperlipidemia and inflammation-related factors of patients with acute coronary syndrome, thereby reduce the incidence of adverse reaction events for patients with cardiovascular disease, and promote the patients＇ prognosis and rehabilitation.
出处
《临床医学工程》
2013年第1期73-74,共2页
Clinical Medicine & Engineering
